In brief
A Nature Medicine modelling study released on Nov. 3, 2026 forecasts worldwide cervical cancer cases to rise 20.2 % and deaths 39.3 % by 2050. The sharp increase will especially hit sub‑Saharan Africa, where cases could almost double. The study urges expanded HPV vaccination, screening and treatment to meet WHO elimination targets.
Australian and international researchers, publishing in Nature Medicine on Nov. 3, 2026, modelled cervical cancer trends for 204 countries and predict a 20.2 % rise in worldwide cases and a 39.3 % rise in deaths by 2050.
In 2023 the world saw about 887,000 new cases and 369,000 deaths. By 2050 the model projects annual cases to hit 1.08 million and deaths to reach 522,000.
The threat is greatest in sub‑Saharan Africa, where cases could grow 88.7 % and deaths 95.4 %, translating to an estimated 206,000 deaths in 2050.
None of the seven global regions is expected to meet the World Health Organization’s elimination threshold of fewer than four cases per 100,000 women by 2050 if current trends persist.
Disparities are stark: in 2023, low‑income countries had incidence rates more than four times higher than high‑income countries, and mortality rates were more than seven times higher.
Authors of the study call for broader access to human papillomavirus (HPV) vaccination, screening and treatment as the most effective measures to curb the projected rise.
The Australian Science Media Center highlighted that the research underscores the urgency of expanding preventative services worldwide.
These findings suggest that, while cervical cancer is largely preventable, inadequate coverage of vaccines and screening programs could lead to the highest burden of disease yet.
